ALN-AGT01 RVR for Healthy Volunteers
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since this study is for healthy volunteers, it's possible that you may not be on any regular medications.
What makes the drug ALN-AGT01 RVR unique compared to other treatments?
ALN-AGT01 RVR, also known as Zilebesiran, is unique because it uses small interfering RNA (siRNA) to target and silence the angiotensinogen gene, which is a novel approach compared to traditional drugs that typically block the effects of angiotensin II. This mechanism allows for a potentially more direct and long-lasting reduction in blood pressure.12345
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.
Eligibility Criteria
This trial is for healthy adult volunteers who want to participate in a study evaluating the safety of a new medication. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of ALN-AGT01 RVR or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ALN-AGT01 RVR
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University